What is the diagnostic approach for a patient from Latin America suspected of having Chagas disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Test for Chagas Disease

Screen all patients from Latin American endemic areas using two different serological tests (IHA, IFA, or ELISA), and confirm positive results with a second test using a different methodology. 1

Who Should Be Screened

Screening is indicated for:

  • All persons from endemic areas in Latin America (21 countries from southern United States to northern Argentina and Chile) 1
  • Children born to mothers from endemic areas (vertical transmission screening) 1
  • Persons with family members diagnosed with Chagas disease 2
  • Persons who have lived in homes of natural material in Latin America 2
  • Persons with history of kissing bug bites 2
  • Blood and organ donors from endemic regions 1

The highest prevalence is found among Bolivian immigrants (10-40%), making this population particularly important to screen 1

Diagnostic Approach by Clinical Phase

Acute Phase (First 1-2 Months After Infection)

  • Direct parasite detection through concentration test or microscopy 3
  • This method is most useful in infants <8 months of age 3
  • Serological tests may be negative early in acute infection 4

Chronic Phase (Most Common Presentation in Migrants)

Two-test serological strategy is mandatory:

  • Use at least two different conventional serological tests from: 1, 5
    • Indirect hemagglutination assay (IHA)
    • Immunofluorescence antibody assay (IFA)
    • Enzyme-linked immunosorbent assay (ELISA)
  • Both tests must be positive to confirm diagnosis 5, 3

Nonconventional assays for treatment monitoring:

  • F29-ELISA (detects antibodies against recombinant flagellar antigens) 5, 3
  • AT-chemiluminescence-ELISA 5
  • These are used to assess treatment response, not for initial diagnosis 5, 3

Critical Testing Pitfalls to Avoid

Do not rely on a single serological test - false positives can occur with leishmaniasis and other parasitic infections, requiring confirmation with a second test using different methodology 1

In endemic areas versus non-endemic areas:

  • Endemic areas: Direct parasite identification is feasible during acute phase 4
  • Non-endemic areas (Europe, North America): Diagnosis relies almost exclusively on serological testing since most cases are chronic and asymptomatic 4

Baseline Evaluation After Positive Serology

Once Chagas infection is confirmed, assess for organ involvement:

Cardiac evaluation (mandatory for all positive patients): 1, 6

  • 12-lead electrocardiogram (look for right bundle-branch block, left anterior fascicular block, complete AV block)
  • Echocardiogram (assess for biventricular enlargement, wall thinning, apical aneurysms, mural thrombi)
  • Cardiac involvement occurs in 19% of infected individuals 1, 4

Gastrointestinal evaluation (if symptomatic): 6

  • Esophageal manometry
  • Barium swallow
  • Barium enema
  • GI involvement occurs in approximately 5% of infected individuals 4

Special Population Considerations

Pregnant women from endemic areas:

  • Screen during pregnancy to identify risk of vertical transmission 1
  • Vertical transmission occurs in 3 of 100 live births 1
  • Test newborns of infected mothers at birth and again after 8 months of age 3

Children <8 months:

  • Use direct parasite detection methods (concentration test) 3
  • Serological tests may reflect maternal antibodies rather than infant infection 3

Children ≥8 months to <18 years:

  • Require positive results on both lysate ELISA and recombinant ELISA for diagnosis 3

The quality of evidence for screening strategies is generally low due to heterogeneity in studied populations, but the recommendation to screen high-risk groups is strong given the significant morbidity (30-40% develop chronic complications) and mortality associated with untreated disease 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Chagas Disease: Epidemiology, Diagnosis, and Treatment.

Current cardiology reports, 2024

Guideline

Chagas Disease Epidemiology and Clinical Manifestations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Chagas disease in Latin American migrants: a Spanish challenge.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.